Establishing an Alzheimer Disease Therapeutics Clinic: Experience From a Year of Evaluations
Year: 2026
Type: article
Study design: Observational Study
Source: Mayo Clinic Proceedings
Authors: Bryan J. Neth, Jonathan Graff-Radford, Petrice M. Cogswell, Derek R. Johnson, Hugo Botha, Stuart J. McCarter, David T. Jones, Megan M. Conkins, Dale B. Hardin, Jodi J. Spence, Carolyn L. Rhegness, Laura A. Allen, Ryan P. Coburn, Johnson D. Pounders, Brian J. Burkett, Jay J. Pillai, Gregory S. Day, Neill R. Graff-Radford, Christian Lachner, Steven A. Messina, Manoj K. Jain, Nikki H. Stricker, Mary M. Machulda, Julie A. Fields, Elizabeth A. Boots, Paula A. Aduen, Leland R. Barnard, Michelle A. Remold, Amanda M. Anderlik, Kayla M. Asleson, Lori L. Martin, Janice A. Klaassen, Jennifer J. Larsen, Alicia Algeciras-Schimnich, Joshua A. Bornhorst, Ande M. Rumilla, Clifford R. Jack, Bradley F. Boeve, David S. Knopman, Ronald C. Petersen, Vijay K. Ramanan
Institutions: Mayo Clinic, Mayo Clinic in Florida
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funders: Mayo Clinic, American Brain Foundation, American Academy of Sleep Medicine Foundation, GHR Foundation, Lewy Body Dementia Association, National Institutes of Health, National Institute on Aging, National Institute of Neurological Disorders and Stroke, Robert and Arlene Kogod Center on Aging
Awards: Mayo Advancing Research Equity in ADRD Study in Jacksonville(MAREAS-Jax), G2909930888, G3357318380, G5285278824, G8032754895, A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-N-methyl-D-aspartate receptor (NMDAR) Encephalitis and Assess Markers of Disease, Mayo Alzheimer's Disease Research Center
OpenAlex ID: W7125481703